ATM and neoplasm: ATRi (VE-821, VE-822, AZ20) resensitized PARPi-resistant BRCA1-mutated human OvC cell line to PARPi [206]AZD6738 efficient in in ATM-deficient cells and in vivo in PDX mouse models with complete ATM loss [208]Combination PARPi with ATRi (AZD6738) and CHEK1i (MK8776) is more effective than PARPi alone in reducing tumor burden in BRCA1/2 mutated HGSOC cells and PDX models [209]